© 1997 by European Society of Cardiology
Copyright © 1997, European Society of Cardiology
The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan
Orion Pharma, Research Center, P.O. Box 65, FIN-02101, Espoo, Finland
* Corresponding author. Fax +358 (9) 429 2924.
Objective: The role of phosphodiesterase III inhibition and calcium sensitization in the cardiac actions of levosimendan, (R)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propane dinitrile, was studied. Methods: Various heart preparations were used to investigate positive inotropy, chronotropy, coronary flow and calcium sensitivity of contractile proteins. The cAMP- and cGMP-dependent protein kinases (PKA and PKG) were inhibited by KT5720 and KT5823, respectively. Furthermore, the synthesis of cAMP was stimulated by forskolin and increased phosphorylation of troponin I was induced by isoprenaline. Results: In Langendorff guinea-pig heart, levosimendan (0.01–1 µM) and milrinone (0.1–10 µM) increased the left ventricular systolic peak pressure almost to the same extent. In the presence of KT5720 (1 µM) milrinone was devoid of positive inotropic activity. In contrast, KT5720 did not antagonize the inotropic effect of levosimendan at 
0.03 µM (= up to the EC50 of levosimendan). The effects of levosimendan and milrinone on heart rate and coronary flow were not affected by KT5720. The PKG inhibitor, KT5823 (1 µM), on the other hand, potentiated the levosimendan-induced increase in coronary flow while it had no effect on the increase induced by milrinone. The mechanical parameters were not affected by KT5823. In the papillary muscle, the positive inotropic effect of milrinone but not that of levosimendan was potentiated by forskolin (0.1 µM). In contrast to milrinone, the positive inotropy by levosimendan was decreased by isoprenaline pretreatment (0.1 µM; 3 min). In line with this, the calcium-sensitizing effect of levosimendan was decreased in skinned fibers prepared from isoprenaline-treated hearts. Conclusions: Our results indicate that the cardiac effects of levosimendan at its therapeutically relevant concentrations were not mediated through PKA or PKG and its positive inotropy is therefore most probably due to the previously reported troponin-C-mediated calcium sensitization of contractile proteins.
KEYWORDS Calcium sensitization; Levosimendan; Protein kinases; KT5720; KT5823; Guinea-pig, heart
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Segreti, K. C. Marsh, J. S. Polakowski, and R. M. Fryer Evoked Changes in Cardiovascular Function in Rats by Infusion of Levosimendan, OR-1896 [(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], Dobutamine, and Milrinone: Comparative Effects on Peripheral Resistance, Cardiac Output, dP/dt, Pulse Rate, and Blood Pressure J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Puttonen, S. Kantele, A. Ruck, M. Ramela, S. Hakkinen, M. Kivikko, and P. J. Pentikainen Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment J. Clin. Pharmacol., April 1, 2008; 48(4): 445 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Banfor, L. C. Preusser, T. J. Campbell, K. C. Marsh, J. S. Polakowski, G. A. Reinhart, B. F. Cox, and R. M. Fryer Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H238 - H248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mebazaa, M. S. Nieminen, M. Packer, A. Cohen-Solal, F. X. Kleber, S. J. Pocock, R. Thakkar, R. J. Padley, P. Poder, M. Kivikko, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial JAMA, May 2, 2007; 297(17): 1883 - 1891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, W. S. Colucci, M. S. Nieminen, B. M. Massie, and M. Gheorghiade Evidence-based use of levosimendan in different clinical settings Eur. Heart J., August 2, 2006; 27(16): 1908 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Greenberg, C. Borghi, and S. Perrone Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? Eur J Heart Fail, January 1, 2003; 5(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. De Witt, I. N. Ibrahim, E. Bayer, A. M. Fields, T. A. Richards, R. E. Banister, and A. D. Kaye An Analysis of Responses to Levosimendan in the Pulmonary Vascular Bed of the Cat Anesth. Analg., June 1, 2002; 94(6): 1427 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Brixius, S. Reicke, and R. H. G. Schwinger Beneficial effects of the Ca2+ sensitizer levosimendan in human myocardium Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H131 - H137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Takahashi, Y. Shimazaki, and M. Endoh Decrease in Ca2+-Sensitizing Effect of UD-CG 212 Cl, a Metabolite of Pimobendan, under Acidotic Condition in Canine Ventricular Myocardium J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1060 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Nieminen, J. Akkila, G. Hasenfuss, F. X. Kleber, L. A. Lehtonen, V. Mitrovic, O. Nyquist, W. J. Remme, and on behalf of the Study Group Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1903 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Slawsky, W. S. Colucci, S. S. Gottlieb, B. H. Greenberg, E. Haeusslein, J. Hare, S. Hutchins, C. V. Leier, T. H. LeJemtel, E. Loh, et al. Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure Circulation, October 31, 2000; 102(18): 2222 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kersten, M. W. Montgomery, P. S. Pagel, and D. C. Warltier Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP Channels Anesth. Analg., January 1, 2000; 90(1): 5 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Du Toit, C. A. Muller, J. McCarthy, and L. H. Opie Levosimendan: Effects of a Calcium Sensitizer on Function and Arrhythmias and Cyclic Nucleotide Levels during Ischemia/Reperfusion in the Langendorff-Perfused Guinea Pig Heart J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 505 - 514. [Abstract] [Full Text]
|
|